华英证券有限责任公司 关于深圳信立泰药业股份有限公司部分募投项目结项 并将节余募集资金永久补充流动资金的核查意见 华英证券有限责任公司（以下简称"华英证券"、"保荐机构"）作为深圳信 立泰药业股份有限公司（以下简称"信立泰"或者"公司"）2020 年非公开发行 A 股股票的保荐机构，根据《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》《深圳证券交易所股票上市规则》及《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，对信立泰 部分募投项目结项并将节余募集资金永久补充流动资金的事项进行了审慎核查。 核查的具体情况及核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许可[2021]663 号文核准《关于核准深圳信 立泰药业股份有限公司非公开发行股票的批复》，公司向特定投资者发行人民币 普通股 68,800,535 股，每股面值 1 元，每股发行价人民币 28.37 元。募集资金共 计人民币 195,187.12 万元，扣除不含税发行费用人民币 1,980.55 万元，实际募集 资金净额为人民币 193, ...

Investment Rating - The report initiates coverage with an "Outperform" rating, projecting a target price of 46.27 RMB based on a 2024 PE of 83x [9][30]. Core Insights - The company is expected to enter a high growth phase for new products, with successful innovation transitions and centralized procurement risks nearly cleared. Innovative drug sales are projected to exceed 1.5 billion RMB in 2024, accounting for nearly 50% of total drug revenue [8][28]. - Two innovative drugs, Rulitan (Aliskiren Amlodipine Tablets) and Xinlitin (Benzoic Acid Faglitin Tablets), have successfully passed the first round of negotiations for inclusion in the 2024 medical insurance catalog, indicating strong market potential [2][8]. Summary by Sections Financial Forecast - Revenue projections for 2024, 2025, and 2026 are 40.38 billion RMB, 44.08 billion RMB, and 56.94 billion RMB, respectively, with year-on-year growth rates of 20.0%, 9.1%, and 29.2%. Net profit is expected to be 6.20 billion RMB, 6.45 billion RMB, and 8.32 billion RMB for the same years [9][30][26]. Product Pipeline - The company is advancing its product pipeline with 6-7 innovative drugs expected to launch between 2024 and 2026, contributing to sustained growth in the innovative drug segment [8][28]. Clinical Development - JK07, an NRG1 fusion antibody, is anticipated to show promising results in chronic heart failure treatment, with global Phase II trials initiated in early 2024 and data expected soon [29][39].

Investment Rating - The report initiates coverage with an "Outperform" rating for the company, assigning a target price of 46.27 CNY based on a 2024 PE of 83x [2]. Core Insights - The company is expected to clear its procurement risks, with only a few generic drug products remaining outside of the procurement system, accounting for a mere 1-2% of sales. The only product with significant decline risk, Cefuroxime Sodium, has recently won a bid in the Jiangsu province procurement, which may lead to a slight decrease in sales next year [1][14]. - The company is successfully transitioning towards innovation and is poised to enter a high-growth phase for new products. The sales revenue from innovative drugs is projected to exceed 1.5 billion CNY in 2024, nearing 50% of the company's total drug revenue. Additionally, 6-7 innovative drugs are expected to be launched from 2024 to 2026, providing continuous growth for the innovative drug business [1][17][63]. Summary by Sections Section 1: Procurement and Innovation Transition - The company is nearing the end of its procurement risks, with only a few generic drugs left outside the procurement system, which represent a low sales volume [1][14]. - The company has a strong pipeline of innovative drugs, with significant growth expected in the coming years, particularly from products like Aliskiren and Teriparatide [1][17]. Section 2: Financial Forecast - Revenue projections for 2024-2026 are 40.38 billion CNY, 44.08 billion CNY, and 56.94 billion CNY, reflecting year-on-year growth rates of 20.0%, 9.1%, and 29.2% respectively. Net profits are forecasted at 6.20 billion CNY, 6.45 billion CNY, and 8.32 billion CNY for the same period [2][63]. - The innovative drug business is expected to generate revenues of 15.10 billion CNY, 23.30 billion CNY, and 35.79 billion CNY from 2024 to 2026, driven by strong performances from key products [63]. Section 3: Clinical Development and Pipeline - The company is focusing on cardiovascular treatments, with several promising candidates in the pipeline, including SAL0120 for resistant hypertension and JK07 for heart failure [18][47]. - JK07, a potential best-in-class NRG1 drug, is currently in global II phase clinical trials, with data expected to be released soon [7][47]. Section 4: Market Position and Competitive Advantage - The company has successfully negotiated to include its innovative drugs in the 2024 medical insurance directory, which is expected to facilitate rapid market penetration and sales growth for products like Aliskiren and Fozagliflozin [25][41]. - The innovative drugs are anticipated to outperform competitors in terms of efficacy and safety, enhancing the company's market position [41][43].

深圳信立泰药业股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002294 证券简称：信立泰 编号：2024-055 深圳信立泰药业股份有限公司（下称"公司"）于近日接到公司控股股东信 立泰药业有限公司（下称"香港信立泰"）的通知，获悉其将所持有的本公司部 分股份解除质押。具体情况如下： 一、本次股东股份解除质押基本情况 | | | 是否为控股 | 本次解除质 | 占其所 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 称 | | 股东或第一 大股东及其 | 押股份数量 | 持股份 | 总股本 | 起始日 | 解除日期 | 质权人 | | | | 一致行动人 | （万股） | 比例 | 比例 | | | | | 信立泰 药业有 | | 控股股东、 第一大股东 | 750.00 | 1.18% | 0.67% | 2022-11-23 | 2024-12-19 | 杭州银行股份 有限公司上海 | | ...

Group 1: Product Development and Market Strategy - The company is focusing on chronic disease areas, particularly cardiovascular, nephrology, and diabetes, with plans to launch 1-2 new products annually, responding to the growing demand due to an aging population [1] - The company aims to maintain competitiveness by providing high-quality drugs that meet clinical needs and by ensuring continuous innovation and risk management [2] - The sales volume of the drug Fuzhuo has exceeded 5000 units, and the management is confident about its sales performance in the coming year [2] Group 2: Financial Performance and R&D Investment - In the first half of 2024, the R&D investment as a percentage of revenue decreased, primarily due to revenue growth, but actual R&D spending has increased after excluding last year's milestone payments [3] - The company plans to continue increasing investment in innovative product development despite the decrease in R&D investment ratio [3] - The number of shareholders as of December 10 is 25,892 [3] Group 3: Cost Management and Operational Efficiency - The company is implementing measures to optimize cost structures in response to rising management and sales expenses, including improving sales efficiency and controlling costs through lean production [4] - The company is focused on maintaining stable gross margins despite fluctuations in raw material costs by optimizing operations and enhancing quality [4] Group 4: Market Expansion and Digital Transformation - The company is exploring digital transformation to enhance internal management efficiency and customer experience [5] - Plans for international clinical new drug applications are in progress, with ongoing evaluations based on project data [5] Group 5: Sales and Marketing Strategies - The company is optimistic about the sales growth of its new products, which are expected to contribute increasingly to revenue and profit [4] - The company anticipates that the two new products will likely participate in medical insurance negotiations next year, which could boost sales [5]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002294 证券简称：信立泰 编号：2024-054 深圳信立泰药业股份有限公司 关于第二期员工持股计划 存续期即将届满的提示性公告 鉴于深圳信立泰药业股份有限公司（下称"公司"）第二期员工持股计划（下 称"本期员工持股计划"）存续期将于 2025 年 6 月 14 日届满，根据中国证监会 《关于上市公司实施员工持股计划试点的指导意见》、深圳证券交易所《深圳证 券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关要 求，现就有关情况公告如下： 一、 第二期员工持股计划概述 1、公司分别于 2020 年 12 月 27 日、2021 年 1 月 21 日召开第五届董事会第 九次会议、2021 年第一次临时股东大会，审议通过了《关于〈深圳信立泰药业股 份有限公司第二期员工持股计划（草案）及摘要〉的议案》等相关议案。 2、第二期员工持股计划的股份来源为公司前期已回购的公司股份，即公司 于 2019 年 11 月 12 日至 2020 年 10 月 5 日期间回购的股份 17,503,178 ...

证券代码：002294 证券简称：信立泰 编号：2024-053 深圳信立泰药业股份有限公司 关于参加 2024 年度 深圳辖区上市公司集体接待日活动的公告 为进一步加强与投资者的互动交流，深圳信立泰药业股份有限公司（下称"公 司"）将参加由深圳证监局和深圳证券交易所指导、深圳上市公司协会与深圳市 全景网络有限公司联合举办的"2024 年度深圳辖区上市公司集体接待日"活动， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2024 年 12 月 12 日（周四）14:30-17:00。 届时公司高管将在线就公司业绩、公司治理、发展战略、经营状况和可持续 发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与。 特此公告 深圳信立泰药业股份有限公司 二〇二四年十二月四日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 董事会 ...

Company and Industry Summary Company Overview - The company is involved in the pharmaceutical industry, focusing on chronic disease medications, particularly for hypertension and diabetes management. Key Points and Arguments Product Development and Market Entry - Two key products have been successfully included in the medical insurance directory, expected to generate approximately 100 million in revenue each within a year [1] - The company anticipates that the sales of these products will exceed initial expectations, with projections of reaching up to 500 million in revenue in the future [1] - The company has a robust pipeline with multiple products expected to launch, including hypertension medications and diabetes treatments, which will enhance the product line significantly [3][4] Clinical Trials and Data Expectations - The company is optimistic about upcoming clinical trial data, with a high probability of positive results expected by the end of December [2] - Safety and efficacy data from ongoing trials show promising results, with no significant differences observed between the treatment and placebo groups [12] - The company is preparing for potential FDA discussions regarding trial data and product approvals [19] Financial Projections - The company expects to achieve revenue growth of 10% next year, with new product launches contributing significantly to this growth [4] - Anticipated revenue for the current year is around 600 million, with projections for next year ranging between 200 to 300 million [25] - The company aims for a long-term growth trajectory of over 20% starting in 2026, driven by new product introductions and market expansion [28] Market Dynamics and Competitive Landscape - The company has a strong position in the hypertension market, with a significant patient population and a well-established product line [6][7] - The competitive landscape is challenging, with many companies vying for market share in chronic disease medications, but the company believes its innovative products will maintain a competitive edge [8][9] - The company is not significantly affected by competitors' failures in similar therapeutic areas, as its products are distinct and have established efficacy [10][22] Innovation and Future Outlook - The company is focusing on innovative drug development, including small molecules and gene editing technologies, to enhance its product offerings [5] - There is a strong emphasis on research and development, with plans to introduce several new products in the coming years [5][17] - The company is also exploring international markets for potential product licensing and partnerships, indicating a strategic approach to global expansion [17] Regulatory and Pricing Strategies - The company is actively engaging with regulatory bodies to ensure compliance and facilitate product approvals [15][19] - Pricing strategies are being carefully considered, with a focus on maintaining competitive pricing while ensuring profitability [13][14] Additional Important Insights - The company is aware of the complexities in the chronic disease medication market, including patient adherence and physician preferences, which will influence product uptake [24] - There is a recognition of the need for ongoing education and marketing efforts to promote new products effectively [22][24] - The company is committed to maintaining a strong cash flow to support ongoing research and development initiatives [8][27]

证券代码：002294 证券简称：信立泰 编号：2024-052 深圳信立泰药业股份有限公司 关于阿利沙坦酯氨氯地平片（复立坦®）、 苯甲酸福格列汀片（信立汀） 新纳入国家医保目录的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 根据国家医保局、人力资源社会保障部发布的《关于印发<国家基本医疗保 险、工伤保险和生育保险药品目录（2024 年）>的通知》（医保发〔2024〕33 号） （下称"《通知》"），深圳信立泰药业股份有限公司（下称"公司"）的创新 药复立坦®（通用名：阿利沙坦酯氨氯地平片）、信立汀（通用名：苯甲酸福格 列汀片），通过谈判新纳入《国家基本医疗保险、工伤保险和生育保险药品目录 （2024 年）》（下称"医保目录"）乙类范围。 具体情况如下： 一、产品情况 （一） 复立坦® 1、 基本情况 药品名称：阿利沙坦酯氨氯地平片 规格：每片含阿利沙坦酯 240mg 与苯磺酸氨氯地平（按氨氯地平计）5mg 医保类别：医保乙类 备注：限原发性高血压。 协议有效期：2025 年 1 月 1 日至 2026 年 12 月 31 日。 （二） 信立汀 1、 ...

普瑞基准科技（北京）有限公司增资的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、交易概述 （一） 基本情况 根据公司战略发展规划，深圳信立泰药业股份有限公司（下称"公司"或"信 立泰"）拟以自筹资金人民币 3,000 万元增资参股公司普瑞基准科技（北京）有 限公司（下称"普瑞基准"或"标的公司"），获得普瑞基准 3.2154%股权。本 次增资完成后，公司将直接持有普瑞基准 8.5745%股权。 增资前，公司及下属控股企业宁波梅山保税港区沃生静嘉股权投资合伙企业 （有限合伙）（下称"沃生静嘉"）、下属参股企业"平潭综合实验区沃生慧嘉 股权投资合伙企业（有限合伙）"（下称"沃生慧嘉"）分别持有普瑞基准 5.5556%、 3.8332%、2.3666%股权。 （二） 董事会审议情况 证券代码：002294 证券简称：信立泰 编号：2024-051 深圳信立泰药业股份有限公司 关于向参股公司 《关于向参股公司普瑞基准科技（北京）有限公司增资的议案》已经公司第 六届董事会第六次会议以 9 人同意，0 人反对，0 人弃权审议通过。 （三） 所必需的审批程序 本 ...